What the FDA labels say about taking them together
Buprenorphine and tranylcypromine
Buprenorphine's FDA label of June 5, 2026 names tranylcypromine in its drug interactions section; the tranylcypromine label PlainMeds reads does not name buprenorphine. The buprenorphine label: “MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity”
Check it at the source: the buprenorphine FDA label on DailyMed (effective June 5, 2026); the tranylcypromine FDA label on DailyMed (effective July 2, 2025, Advanz Pharma (US) Corp.).
What does the buprenorphine label say about tranylcypromine?
Buprenorphine label, drug interactionsMonoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (…). Intervention: The use of buprenorphine sublingual tablets is not recommended for patients taking MAOIs or within 14 days of stopping such treatment. Examples: Phenelzine, tranylcypromine, linezolid
Source: FDA drug label (Brixadi, NDA210136), Braeburn Inc., effective December 31, 2025 (SPL set 5d8a8fd0-8619-422a-a664-d1d2e8970f48), via openFDA
Source: FDA drug label (Butrans, NDA021306), Knoa Pharma LLC, effective May 1, 2026 (SPL set 794aa355-66de-41b8-aedf-f2c40f6bc664), via openFDA
Source: FDA drug label (Sublocade, NDA209819), Indivior Inc., effective July 27, 2026 (SPL set 6189fb21-9432-45f8-8481-0bfaf3ccde95), via openFDA
Source: FDA drug label (Buprenorphine HCl), SpecGx LLC, effective June 5, 2026 (SPL set b60d514d-a88a-4fa2-a5b0-30ac29e04973), via openFDA; the full label on DailyMed
What does the tranylcypromine label say about buprenorphine?
Tranylcypromine's label (effective July 2, 2025) does not name buprenorphine in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (PARNATE), Advanz Pharma (US) Corp., effective July 2, 2025 (SPL set b72d8187-dfcc-4ea0-b5e9-c0be95b69a27), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Buprenorphine | Tranylcypromine | |
|---|---|---|
| Labeled for | Opioid use disorder, Pain | Depression |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.277 per tablet 2 mg tablet sl | $0.591 per tablet 10 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once